Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ADUS vs AHCO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ADUS Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

ADUS Overall Winner 6-Pillar Tally: ADUS 3 – 3 AHCO Matrix Metrics: ADUS 7 – 3 AHCO

As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ADUS vs AHCO
ADUS NASDAQ Head-to-Head Winner
Addus HomeCare Corp.
Services-Home Health Care Services
$122.50
+1.18% 1D
Market Cap $2.3B
TTM Revenue $1.50B
Forward P/E 16.1x
Beta / 30D Vol -0.07β · 21% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 57.0 Fund 52.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 52
RSI-14: 51.6 · SMA20: $123.87 · SMA50: $118.74
AHCO NASDAQ
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32

6-Pillar Scorecard Institutional Category Breakdown (ADUS 3 – 3 AHCO)

Columns: Metric · ADUS · AHCO
1. Valuation Multiples AHCO
Forward P/E 16.1x 7.8x
Trailing P/E 20.1x 7.8x
PEG Ratio 1.05x N/M
EV / Revenue 1.5x 0.9x
2. Growth & Scale AHCO
Revenue Growth (YoY) +7.0% +10.9%
Earnings Growth (YoY) +24.2% +6.7%
TTM Revenue (USD) $1.50B $3.44B
Market Cap $2.3B $989.8M
3. Profitability & Quality ADUS
Gross Margin 32.3% 18.2%
Operating Margin 10.4% 3.8%
Net Profit Margin 7.4% -11.8%
Return on Equity (ROE) 10.0% -28.4%
4. Balance Sheet & Cash Flow ADUS
Cash Generation (TTM) $173M EBITDA $82M
Cash Flow Margin 11.5% EBITDA Mgn 2.4%
Net Cash / Leverage $64.64 Book/Sh · 10.0% ROE $1.97B Net Debt (1.67x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AHCO
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 21.9% (16th %ile) 66.9% (12th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ADUS
OpEx & R&D Intensity 21.9% of Rev ($329M) 14.4% of Rev ($495M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ADUS (7) vs AHCO (3)
Institutional Metric ADUS AHCO Criterion Row Edge
Market Capitalization
Scale
$2.3B $989.8M Larger Scale ADUS
Trailing P/E Ratio
Valuation
20.1x 7.8x Lower Multiple AHCO
Forward P/E Ratio
Valuation
16.1x 7.8x Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+7.0% +10.9% Higher Growth AHCO
Operating Margin (TTM)
Profitability
10.4% 3.8% Higher Margin ADUS
Net Profit Margin
Profitability
7.4% -11.8% Higher Margin ADUS
Return on Equity (ROE)
Capital Efficiency
10.0% -28.4% Higher ROE ADUS
52-Week Range Position
Momentum
79% ($88–$132) 24% ($5–$13) Stronger Trend ADUS
Beta / 30D Volatility
Risk Regime
-0.07β · 21% Vol 0.17β · 67% Vol Lower Realized Risk ADUS
Unified Institutional Score
Composite Signal
59.0 / 100 (HOLD) 45.2 / 100 (HOLD) Higher Composite ADUS
Trailing 12M Revenue (USD)
Operating Scale
$1.50B $3.44B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
32.3% 18.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.05x PEG · 1.5x EV/Rev N/M PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$173M EBITDA ($64.64 Book/Sh · 10.0% ROE) $82M ($1.97B Net Debt (1.67x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +16.83 pp
ADUS: -0.14% · AHCO: +16.69%
3M Horizon AHCO +26.5 pp
ADUS: +1.39% · AHCO: +27.89%
6M Horizon ADUS +63.32 pp
ADUS: +32.22% · AHCO: -31.1%
1Y Horizon ADUS +33.27 pp
ADUS: +12.39% · AHCO: -20.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ADUS vs AHCO. Trailing 12-month operating profitability (ADUS 10.4% vs AHCO 3.8%) and valuation multiples (ADUS 16.1x vs AHCO 7.8x Forward P/E) are benchmarked directly in Pillar 4 below.

ADUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.50B
Gross Margin32.3%
Op. Margin10.4%
ROE / Fwd P/E10.0% · 16.1x
AHCO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.44B
Gross Margin18.2%
Op. Margin3.8%
ROE / Fwd P/E-28.4% · 7.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ADUS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.9%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ADUS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.3B market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 21.9% of Rev ($329M)
90D Engineering Disclosures 0 Published
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published

Investor FAQ ADUS vs AHCO Key Questions & Quantitative Answers

As of Nov 20, 2026, Addus HomeCare Corp. (ADUS) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ADUS carries a Unified Composite Score of 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin), whereas AHCO carries 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin). Technically, ADUS sits in a Markup phase (RSI 51.6, UNCLASSIFIED options structure) and AHCO sits in a Markup phase (RSI 57.1, SURGE options structure).

AHCO leads the Growth & Scale pillar: ADUS posts +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin), compared with AHCO at +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin). On trailing 12-month operating scale, ADUS generates $1.50B in USD-normalized revenue versus $3.44B for AHCO. In operating R&D and SG&A reinvestment, ADUS deploys 21.9% of Rev ($329M) (0 90-day corporate R&D disclosures) versus 14.4% of Rev ($495M) (0 disclosures) for AHCO.

AHCO screens cheaper on headline valuation multiples. ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin), whereas AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ADUS (10.0% ROE) versus AHCO (-28.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk). By comparison, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.